Bio News
Australia-based Telix said it will acquire all outstanding shares of German radiopharmaceutical developer ITM for $1.65 billion (approximately 2.2 trillion won). Telix will pay an additional $700 million if ITM’s lead candidate, ITM-11, achieves its approval and sales targets. The transaction is expected to close by the end of fiscal 2026, giving the combined company an isotope production and distribution network spanning more than 65 countries.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
